A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
|Articles|July 15, 2022
Daily Medication Pearl: Oritavancin (Orbactiv)
Author(s)Saro Arakelians, PharmD
Advertisement
Medication Pearl of the Day: Oritavancin (Orbactiv)
Indication: Oritavancin (Orbactiv) is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms.
Insight:
- Dosing:Administer 1200 mg of oritavancin as a single dose by intravenous infusion over 3 hours.
- Dosage forms: For injection 400 mg of lyophilized powder in a single-dose vial for reconstitution.
- Adverse events:The most common adverse reactions (≥3%) in patients treated with oritavancin were headache, nausea, vomiting, limb and subcutaneous abscesses, and diarrhea.
- Mechanism of action:Oritavancin has 3 mechanisms of action: (1) inhibition of the transglycosylation (polymerization) step of cell wall biosynthesis by binding to the stem peptide of peptidoglycan precursors; (2) inhibition of the transpeptidation (crosslinking) step of cell wall biosynthesis by binding to the peptide bridging segments of the cell wall; and (3) disruption of bacterial membrane integrity, leading to depolarization, permeabilization, and cell death.
Advertisement
Related to this article
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
2
Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines
3
Glucose Monitoring: Timing Makes Every Reading Count
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5